Plasma biomarkers of Alzheimer’s disease predict cognitive decline and could improve clinical trials in the cognitively unimpaired elderly

Autor:	Shorena Janelidze, Antoine Leuzy, Oskar Hansson, Niklas Mattsson-Carlgren, Anna L. Svenningsson, Jeffrey L. Dage, Erik Stomrud, Nicholas C. Cullen, Sebastian Palmqvist
Rok vydání:	2021
Předmět:	Oncology medicine.medical_specialty Amyloid business.industry Neurofilament light Neurodegeneration Cognition Disease Plasma biomarkers medicine.disease Clinical trial Internal medicine medicine Cognitive decline business
DOI:	10.1101/2021.01.22.21250293
Popis:	Plasma biomarkers of amyloid, tau, and neurodegeneration (ATN) need to be characterized in cognitively unimpaired (CU) elderly indviduals. We therefore tested if plasma measurements of amyloid-β (Aβ)42/40, phospho-tau217 (P-tau217), and neurofilament light (NfL) together predict clinical deterioration in 435 CU individuals followed for an average of 4.8 ±1.7 years in the BioFINDER study. A combination of all three plasma biomarkers and basic demographics best predicted change in the cognition (Pre-Alzheimer’s Clinical Composite; R2=0.14, 95% CI [0.12-0.17]; P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::17ac050c91b6f52feb523d1362ac5d56 https://doi.org/10.1101/2021.01.22.21250293 Zobrazit plný text záznamu